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Conclusion Administration of TG causes an acute vasodi-
lation and improves arterial stiffness probably due to non-
genomic actions of T. Endothelial vasodilatory response 
was more pronounced depending on higher plasma TT and 
DHT levels attained. Clinical implications in elderly frail 
populations are discussed.
Keywords Male hypogonadism · Cardiovascular · 
Reactive hyperemia index · CAG repeat · Treatment
Introduction
The endothelium is a single layer of cells that line the 
luminal surface of blood vessels. In a normal physiologic 
state, healthy endothelium serves as an anticoagulant mem-
brane, exerting predominantly fibrinolytic, anticoagulant 
and anti-aggregation effects [1]. The vascular endothelium 
also plays an obligatory role in vasodilation by the action 
of endothelial-derived nitric oxide (NO). The presence of 
different cardiovascular risk factors (CRFs), such as aging, 
smoking, hypertension, dyslipidemia, diabetes, obesity and 
some less traditional factors (e.g., inflammation, hypoxia, 
oxidative stress and hyperhomocysteinemia), is known to 
cause endothelial dysfunction (EDys) [2]. EDys frequently 
occurs in acute coronary syndromes [3], heart failure and 
erectile dysfunction [4]. EDys is characterized by signifi-
cant modifications in the physiological and biochemical 
parameters in the endothelium. These include: vascular 
stiffness, increased vascular tone, production of inflam-
matory cytokines, increased permeability, susceptibility 
to invasion of immunocytes, decrease in endothelial cell 
growth and dysregulation of fibrinolytic factors.
Exploration of the brachial artery flow-mediated dilation 
(FMD) capability is the most commonly used technique 
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for investigation of endothelial function. Flow-mediated 
dilation serves as an index of NO-mediated endothelium-
dependent vasodilator function [5, 6]. Recently, an alterna-
tive method, reactive hyperemia peripheral arterial tonom-
etry (PAT), has been used to indirectly identify patients 
with coronary endothelial dysfunction by measuring pulse 
volume changes at the fingertips after an occlusion of the 
brachial artery of the dominant arm. This method showed a 
significant correlation with FMD (r = 0.55, p < 0.0001) [7]. 
The PAT evaluates the amplitude of the arterial pulse wave 
at the fingertip; this is a non-invasive, operator-independent 
technique which allows plethysmographic recording of the 
pulse wave amplitude that corresponds to the modifications 
of the pulsatile blood volume. Reactive hyperemia has been 
showed to be an adequate surrogate marker useful for mon-
itoring the changes of vascular function; in the Framing-
ham cohort, PAT measurement proved to be closely 
related with the cardiovascular risk factors. In addition, a 
number of other studies showed a relation between coro-
nary EDys, assessed through invasive methods and results 
obtained through PAT [8]. EDys is a systemic process and 
the assessment of the functional endothelium-dependent 
capability of the peripheral arteries represents a chance to 
examine in depth the functional status of the whole circula-
tory system [9].
There are pre-clinical and clinical scientific evidences 
that correlate EDys with androgen deficiency [10]. Sev-
eral in vitro studies examined the physiological mecha-
nisms of the androgen-mediated vasodilation in various 
animal and human blood vessels, showing that the relax-
ing effects of T and 5α-DHT on vascular and non-vascular 
smooth muscles might probably be due to inhibition of the 
L-type calcium channels [11]. In some studies, 5α-DHT 
proved to be more powerful than T in eliciting relaxation 
of KCl-induced contractions. T, at nanomolar concen-
trations, showed to be a potent L-type voltage-operated 
calcium channels (L-VOCCs) antagonist ascribable to a 
5α-DHT selective block. Akishita et al. in a cohort of 187 
men demonstrated that the percentage of FMD in the high-
est quartile of free testosterone was 1.7-fold higher than 
that in the lowest quartile [12]. In particular, serum total 
and free testosterone (TT and FT, respectively) and dehy-
droepiandrosterone sulfate (DHEA-S) concentrations were 
significantly correlated with the percentage of FMD inde-
pendently from other risk factors such as age, body mass 
index (BMI), hypertension, dyslipidemia and diabetes. 
Foresta et al. showed that transdermal-T administration 
was able to increase the number of circulating endothelial 
progenitor cells [13]. Jones et al. reported that T treatment 
in male patients with cardiovascular disease was related 
with an improvement of vascular reactivity, suggesting 
that this can be true only for pathologic blood vessels [14]. 
We recently demonstrated that long-term T administration 
in obese hypogonadal men is able to improve metabolic 
parameters as well as endothelial function and that a 
6-month withdrawal reverts most of the beneficial effects 
[15].
Despite these studies, the effects of T on vascular reac-
tivity may be also dependent on the variable number of 
CAG repeats in exon 1, which encodes a polyglutamine 
tract in the amino-terminal domain of the androgen recep-
tor (AR) present in human vessels of healthy subjects [16]. 
The present study was designed to investigate the acute 
effects of T administration on vascular parameters in young 
severe hypogonadal men of any origin, and the possible 




Ten men affected by severe hypotestosteronemia, after a 
pharmacologic T treatment washout period of 4 weeks, 
were enrolled. The main features of the enrolled subjects are 
reported in Table 1. All the subjects were non-smoking and 
normal weight. Patients with primary hypogonadism were 
affected by Klinefelter’s syndrome (n = 1) and bilateral 
orchiectomy because of testicular cancer (n = 3), while six 
out of ten were affected by secondary hypogonadism.
Inclusion criteria were age greater than 18 years and 
serum total testosterone (TT) level <1 ng/mL (3.5 nmol/L) 
at time 0, confirmed at two different times. Exclusion cri-
teria were the following: past events of cardiomyopathy, 
stroke and deep venous thrombosis; change of therapy in 
the last 6 months; prostate or breast cancer; high values 
of PSA (adjusted for age); digital rectal examination sug-
gestive of prostate cancer; severe obstructive symptoms of 
benign prostate hyperplasia (IPSS > 18); hematocrit level 
>52 % at time 0; previous or present signs of chronic liver 
or kidney disease, hematological disorders, hyperprol-
actinemia or other endocrine disorders (i.e., “empty sella 
syndrome”, MR-detected pituitary masses); other condi-
tions hazardous to the health of patients. Written informed 
Table 1  Baseline demographic features of enrolled subjects
n = 10
Age (years) 31 ± 9
Systolic blood pressure (mmHg) 103 ± 10
Diastolic blood pressure (mmHg) 70 ± 13
Body mass index (BMI, kg/m2) 22 ± 3
Subjects with primary hypogonadism 4
Subjects with secondary hypogonadism 6
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consent was obtained before commencement of the study, 
according to Protocol and Good Clinical Practice (GCP) 
on the conducting and monitoring of clinical studies and 
approved by our internal review board.
Study design and main outcome measures
This randomized, double-blind, crossover, placebo-con-
trolled study used a fixed dose (4 g at 2 %) of transdermal-
T gel (TG; 80 mg testosterone daily—Tostrex®) or as an 
alternative an equivalent dose of placebo gel for four con-
secutive days. Each subject received the same information 
about how to correctly use the gel preparation that should 
have been applied in the early morning (between 8:00 and 
9:00 a.m.), after shower or bathing, on hairless skin.
Each subject underwent endothelial function assessment 
through peripheral arterial tonometry (PAT; EndoPAT2000, 
Itamar Medical, Caesarea, Israel) according to previously 
published procedure [17] and blood sample at times 0, +4 
and +96 h (the latter before gel administration) were inves-
tigated. In each blood sample, the following substances were 
dosed: TT, DHT, FT, 17β-estradiol (E2) and sex hormone 
binding globulin (SHBG). At the end of each treatment, 
all patients were shifted to an alternative treatment after a 
washout period of 7 days to avoid any accumulation effect. 
Blood samples were centrifuged and immediately frozen at 
−20 °C. Each test was performed in duplicate. TT and E2 
were measured through chemiluminescence microparticle 
immunoassay (CMIA, Architect System, Abbott Laborato-
ries, IL, USA), with a detection limit of 0.28 nmol/L and 
10 pg/mL, respectively (intra- and interassay coefficients of 
variation for TT: 2.1 and 3.6 % at 10.08 nmol/L), with ref-
erence values 2.8–11 ng/mL (T) and 25–107 pg/mL (E2). 
Serum concentrations of SHBG were measured through 
radioimmunoassay (Radim S.p.A., Pomezia, Roma, Ita-
lia), with detection limit of 0.26 nmol/L, intra- and interas-
say coefficients of variation 2.8 and 4.1 % at 26.4 nmol/L 
and reference values 9–54 nmol/L. FT concentrations were 
assessed through radioimmunometric assay (RIA) (DIA 
Source ImmunoAssays S.A.—Louvain-la-Neuve, Belgio), 
with detection limit of 0.13 pg/mL, intra- and interassay 
coefficients of variation 5.7 and 6.7 % at 10.89 pg/mL and 
reference values 8.9–42.5 pg/mL. Serum concentrations of 
DHT were measured by radioimmunoassay (RIA) using 
commercial RIA kits (Diagnostic System Laboratory, Web-
ster, TX, USA), with an intra- and interassay coefficient of 
variation of 3.7 and 6.9 %.
The polyglutamine and polyglycine segment polymor-
phism of the AR gene (CAG and GGC repeats) was also 
performed in all subjects. Genomic DNA extraction and 
analysis of the length of the polymorphic fragments were 
performed according to a previously published procedure 
[18].
Primary end points were variations from baseline of 
the hyperemic response (RHI) as calculated by fingertip 
peripheral arterial tonometry (EndoPAT2000) and of the 
augmentation index (AI).
Also, the study of androgen receptor polymorphisms, via 
measurement of “CAG repeats” length, was performed to 
evaluate the possible relationship with vascular responses.
Statistical analysis
All results are reported as mean ± standard error (SE). Sta-
tistical differences for single between-group comparisons 
were studied using t tests for non-paired data. Multiple 
regression analysis was performed to assess values of RHI 
and AI in comparison with values of TT and FT (at times 0, 
+4 and +96 h) and values of ΔRHI and ΔAI in compari-
son with values of ΔTT and ΔFT; the same statistical anal-
ysis was performed also for values of length of sequence of 
CAG triplets (CAG repeats) in comparison with values of 
RHI and the natural logarithm (LnRHI), at times 0, +4 h 
and +96 h. Statistical analysis was performed using soft-
ware SPSS 17.0 (SPSS Inc., Chicago, IL, USA). A p value 
<0.05 was considered to be statistically significant.
Results
4 and 96 h after starting treatment with TG, 80 mg daily, 
serum TT, FT and DHT levels showed a statistically signifi-
cant increase compared to the basal values for all subjects, 
(p < 0.0001, p < 0.001 and p < 0.001, respectively; Table 2). 
No statistically significant change in E2 and SHBG levels 
was found (Table 2). RHI and LnRHI showed a statistically 
significant increase (mean ± SE) only at time +4 h com-
pared to the basal value (p < 0.01 and p < 0.001 Fig. 1a, b, 
respectively). Also, AI and AI@75 values showed a statis-
tically significant reduction compared to baseline at +4 h 
(p < 0.01) and +96 h (p < 0.01 and p < 0.001, Fig. 1c, d 
respectively). An inverse correlation was found between 
TT and AI (p < 0.03; r = −0.31; Fig. 2a) and AI@75 
(p < 0.04; r = −0.29; Fig. 2b); similarly, an inverse corre-
lation was found between FT and AI (p < 0.02; r = −0.32; 
Fig. 2c) and AI@75 (p < 0.04; r = −0.29; Fig. 2d). No hor-
monal and vascular differences were found after placebo 
treatment.
Interestingly, a direct correlation was found between 
ΔTT and ΔRHI (p < 0.04; r = 0.37; Fig. 3a). Accordingly, 
an inverse correlation was found between ΔTT and ΔAI 
(p < 0.05; r = −0.35; Fig. 3b), ever after normalization for 
heart rate, ΔAI@75 (p < 0.03; r = −0.38; Fig. 3c), and 
between ΔDHT and ΔRHI (p < 0.005; r = −0.17; Fig. 3d). 
Furthermore, a direct correlation was found between “CAG 
repeats” length and LnRHI (Fig. 4a) and only after +96 h 
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between “CAG repeats” and ΔLnRHI (p < 0.03; r2 = 0.47) 
(Fig. 4b). No serious adverse events were reported.
Discussion
This is the first study to our best knowledge that evalu-
ated the acute (+4 and 96 h) vascular effects of T admin-
istration in young hypogonadal men through non-invasive 
digital peripheral arterial tonometry (PAT). We found that 
the administration of a fixed dose of 80 mg TG promptly 
restored T plasma levels and improved endothelial func-
tion, depending also on AR CAG repeat lengths. Our 
results show a statistically significant acute improvement 
of endothelial function as evaluated by PAT, with a con-
comitant reduction of the arterial stiffness. Indeed, Webb 
et al. had previously demonstrated similar acute effects 
after intracoronary administration of physiological T 
Table 2  Differences in hormonal levels in different treatment groups
Testosterone treatment arm p Placebo arm p
Time 0 Time +4 h Time +96 h Time 0 Time +4 h Time +96 h
Total T (ng/mL) 0.71 ± 0.48 4.55 ± 2.13*** 1.96 ± 0.68** p < 0.0001***
p < 0.001**
0.58 ± 0.43 0.55 ± 0.26 0.55 ± 0.46 ns
Free T (pg/mL) 1.6 ± 1.8 10.1 ± 5.2*** 5.2 ± 2.6** p < 0.0001***
p < 0.001**
1.54 ± 1.3 1.2 ± 0.75 0.72 ± 0.51 ns
DHT (pg/mL) 305 ± 140 553 ± 105** 410 ± 141* p < 0.001**
p < 0.01*
330 ± 150 312 ± 138 328 ± 152 ns
E2 (pg/mL) 11.1 ± 1.7 12.1 ± 4.8 14.6 ± 4.5 ns 10.8 ± 2.05 10.8 ± 1.6 10.3 ± 10.5 ns
SHBG (nMol/L) 34.6 ± 12.7 35.7 ± 12.8 33.7 ± 12.7 ns 35.5 ± 7.1 32.7 ± 12.8 32.6 ± 7.5 ns
Fig. 1  Reactive hyperemia index (RHI) and augmentation index (AI) in the T treatment arm (*p < 0.01; **p < 0.001)
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concentrations, by inducing coronary artery dilatation and 
increases in coronary blood flow in men with established 
coronary artery disease (CAD). Despite that in vitro and 
in vivo studies in animals support the hypothesis that T 
can lead to endothelium-independent vasodilation mecha-
nisms through a direct interaction with K+ or Ca2+ chan-
nels, the results of that study were pivotal to hypothesize 
an indirect, endothelium-dependent mechanism of action 
of T [19].
It has been suggested that E2 has vasodilator proper-
ties through NO endothelial production and direct smooth 
muscle relaxation [20], but also T has been shown to cause 
vasodilatation by direct interaction with ion channels 
within the vascular smooth muscle cell membrane [21], 
Fig. 2  Correlations between 
augmentation index (AI) and 
androgen levels
Fig. 3  Correlations between 
TT and DHT vs. variations of 
EndoPAT parameters
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i.e., through inhibition of l-type voltage-gated calcium 
channels (VGCCs) [11]. This evidence has been noticed in 
clinical trials reporting reduction in blood pressure occur-
ring in hypogonadal man treated with T [22]. The absence 
of E2 variations observed in our study seems to exclude the 
involvement of estrogens in the acute vasodilatory effects 
reported by T administration. Thus, these latter effects 
might be directly due to T-induced non-genomic effects on 
arterial vasodilation that are in accordance with the results 
of several preclinical and clinical studies. Additionally, the 
direct relationship with CAG repeats found in our results 
after 96 h could explain some genomic (late) effects of 
T replacement therapy, in accordance with the potential 
chronic therapeutic protective effect on CAD as shown in 
previous studies [19].
Two distinct and large bodies of literature exist on 
resilience that are of potential interest for surgical out-
comes: first, literature on the impact of resilience on sur-
gical recovery and wound healing; second, literature on 
biomarkers for resilience, which largely focuses on neu-
ropeptide Y, dehydroepiandrosterone and T [23]. By iden-
tifying surgical resilience, there is potential for utilizing 
these biomarkers as prognostic indicators of likely recov-
ery trajectories from surgery, which in turn complement 
individualized peri-operative management. As such, T 
represents one of the most prominent biomarkers and 
its short-term administration may represent a challenge 
for some categories of patients after surgery. Yaron et al. 
firstly demonstrated that low T serum levels were directly 
correlated with increased arterial stiffness and that restor-
ing normal T serum levels with 1 % transdermal-T (25–
50 mg daily) was able to improve endothelial function 
after 48 h and 90 days [24]. Hu et al. reported that middle-
aged male patients with CAD presented lower levels of 
serum T and that testosterone level was negatively corre-
lated with the severity of coronary artery stenosis; patients 
with acute myocardial infarction were found to have the 
lowest T levels (365.3 ng/dL) in the series. T levels were 
also found to be independent predictors for CAD (odds 
ratio 0.311, 95 % confidence interval 0.174–0.512) [25]. 
Atish et al. also found that long-term testosterone replace-
ment therapy could decrease angina threshold and promote 
plaque stability in men. These results suggested that lower 
T level could be involved in the pathogenesis of CAD 
and exogenous T replacement therapy may be a potential 
therapeutic approach for CAD [26]. The results from our 
study suggest that T supplementation could be a potential 
approach for both patients after surgery resilience or myo-
cardial infarction; a short challenge of T could improve 
their potential vasodilatory responses to conventional 
treatments and their recovery.
With regard to T abuse, we might hypothesize that a 
rapid effect of exogenous T administration on the vascular 
system could also contribute to an acute muscular perfor-
mance improvement in athletes abusing a single TG admin-
istration during prolonged aerobic competition.
The present study has some limitations. The number of 
patients studied is low, so that major conclusions on CAG 
number repeats and its relationship with vascular param-
eters cannot be obtained. Nevertheless, severe young hypo-
gonadal patients are difficult to enroll because of the low 
incidence of disease, but they represent a population that 
is often free from potential confounding factors, i.e., con-
comitant drug assumption. We are aware that increasing the 
number of subjects studied could have a different impact on 
the present findings.
Conclusions
We demonstrated for the first time that acute TG adminis-
tration in severe hypogonadal men improves arterial vaso-
dilatory responses in a concentration-dependent manner 
along with improvements in arterial stiffness. These rapid 
effects (4 h) are lost at 96 h when a relationship between 
endothelial response and AR polymorphism is found. 
Potential cardiologic, post-surgical and sports endocrinol-
ogy implications remain to be fully elucidated. Our results 
might lead to further studies aimed at evaluating the effects 
of acute T administration in patients affected with CAD or 
Fig. 4  Correlations between 
“CAG repeats” and variations of 
natural logarithm of RHI
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in post-surgical recovery and, in particular, in elderly men 
affected by late-onset hypogonadism.
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